|
|
 | | | |
- close
- close
- close
- close
The Times of India
Mar 19
Comment
Natco Pharma’s success in getting the country’s first compulsory licence approval on exorbitantly-priced cancer drug—Nexavar—has paved the way for another generic company to follow suit.
The Hindu Business Line
Mar 5
Comment
It is the strategy to go after niche and difficult-to-make products, that catapulted Hyderabad-based drug maker Natco Pharma onto the national healthcare landscape. Run by a mana...
Reuters
Mar 5
Comment
Reuters Market Eye - Shares in Natco Pharma Ltd surge 5.3 percent after an Indian patent appeals board upheld on Monday a decision to allow the company to sell a generic version of Bayer AG's cancer drug Nexavar.
The Hindu Business Line
Mar 5
Comment
Shares of Natco Pharma Ltd (NPL) surged 7.89 per cent to Rs 459.90 in early trading on the NSE today, riding on the positive momentum created by the decision of the Intellectual Property Appellate...
The Hindu Business Line
Mar 4
Comment
In a decision that will bring cheer to cancer patients, the Intellectual Property Appellate Board has held that Natco can continue to make and sell a generic version of Bayer’s kidney cancer drug...
The Economic Times
Feb 13
Comment
Natco Pharma today reported 32.88 per cent increase in consolidated net profit at Rs 22.59 crore for its third quarter ended December 31.
The Hindu Business Line
Dec 19
Comment
Natco Pharma Ltd has received approval from the US Food and Drug Administration for its abbreviated new drug application for Lansoprazole delayed release capsules for the prescript...
The Hindu Business Line
Nov 29
Comment
Natco Pharma scrip touched an all-time high at Rs 468 a share on the bourses on Thursday. The triggers for the scrip’s rise were mainly the dismissal of the British drug maker, AstraZene...
The Hindu Business Line
Nov 11
Comment
Natco Pharma Ltd has announced that it acquired 51 per cent of the paid-up equity capital of Natco Organics. Natco Organics is a joint venture between Natco Pharma and TIDCO. In a notice to the st...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
